+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Real World Evidence Solution Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031

  • PDF Icon

    Report

  • 116 Pages
  • April 2023
  • Region: Global
  • Acute Market Reports
  • ID: 5772630
Description Jump to:
The global market for real-world evidence solutions is expected to grow at a CAGR of 15% during the forecast period of 2023 to 2031. This market's expansion is primarily driven by the primary factors driving the growth of this market are the expansion of clinical trials and the change from volume-based to value-based treatment. Utilizing RWE and RWD can improve protocol design, hence reducing the number of costly protocol changes, and enabling the creation of synthetic control arms to speed up trial execution and save expenses. Similarly, RWE can expedite label expansion and reduce the overall cost of filing-required documentation. Due to these benefits, the adoption of RWE systems in drug and medical device research and development is increasing. Support from regulatory bodies for the use of Real-World Evidence (RWE) solutions and a rise in R&D expenditures are expected to stimulate market growth. In addition, the shift from volume-based to value-based care is anticipated to contribute to the rise. As a result of the COVID-19 pandemic, numerous market participants began to experience widespread business disruptions, which hindered routine corporate operations.

Increased Investment in Research and Development

The majority of pharmaceutical, biopharmaceutical, and medical device businesses continue to make substantial investments in the development of novel medications and technologies. Particularly, the pharmaceutical business is heavily invested in R&D. To meet the demands of both drug discovery and development, pharmaceutical and biopharmaceutical businesses are opting for fully integrated or functional outsourcing services, from the early development phase to the late-stage development phase, due to increased R&D expenditures. The pharmaceutical industry spends the highest proportion of its income on research and development compared to all other industries. This increase in R&D spending, spurred by the requirement for multiple preclinical and clinical services during the drug development process, is anticipated to fuel the expansion of the RWE market.

Medical Practitioners and Academics' Reluctance to Rely on Real-World Evidence Solutions

Despite the widespread use of RWE across applications, certain stakeholders continue to be hesitant to rely on real-world evidence. For instance, although payers have begun using RWE, they prefer to base drug coverage decisions on randomized clinical trials (RCTs) rather than external observational data. The primary reason for this preference is the provision of numerous standards and methodologies for examining clinical experience evidence derived from actual patient care. In addition, payers utilize a wide range of procedures and evidence when determining pharmaceutical coverage. During the pharmaceutical technology assessment (PTA) procedure, these differences can impact reimbursement, patient access, and potential healthcare outcomes. Therefore, stakeholders are hesitant to use evidence without a standardized data-gathering strategy.

Increased Emphasis on RWE's End-To-End Services

As players in the healthcare business seek innovative solutions to address the unsustainable cost burden and relatively low return on investment, the healthcare ecosystem is transforming, and there is a growing focus on healthcare costs. To demonstrate value, businesses require robust capabilities in evidence lifecycle management. Consequently, an opportunity for an end-to-end approach to leverage the data, evidence, and knowledge assets of a life sciences organization has been created, which is aiding in the dismantling of conventional silos and enabling insight-driven decision-making from the product R&D phase to its commercialization. This entails creating an effective governance plan and using technologies like cloud and self-service analytics, as well as acquiring the capacity to integrate data sets and comprehend the relevant resources for the required analytics (and tactical issues around data access and quality).

Absence Of Globally Acknowledged Methodology Standards and Data Processing Infrastructure

In this sector, the lack of globally agreed standards or principles that may be used in the design, analysis, and reporting of RWE has become a serious obstacle. This lack of unanimity has resulted in RWE not being of sufficient quality to be included in the body of evidence used to compare the efficacy of various treatment approaches. This has decreased the potential value of the produced information, hence decreasing the incentive to produce it. This further diminishes the likelihood that significant stakeholders will use RWE solutions.

In 2022, The Services Category Dominated the RWE Solutions Market

The rising requirement to translate data into actionable evidence and the availability of a vast quantity of healthcare data are the primary reasons driving the expansion of this market sector. Clients can save time and money by relying on vendors to tailor their services to their specific needs, as opposed to acquiring data sets and analyzing them to generate valuable information. Consequently, the demand for RWE services is greater than that for RWE data sets. Experts in RWE communicate and work with the subject matter expert of pharmaceutical and medical device firms to provide services to establish intelligent RWE plans (consulting services) and employ analytical capabilities to provide significant statistical insights.

In 2022, The Drug Development and Approvals Segment Led the RWE Solutions Market

Due to the increasing number of clinical studies in oncology and cardiovascular medicines, the drug development and approvals market segment is the most significant. In addition, post-pandemic treatment advancements for the COVID-19 infection had a substantial increase. This division is further subdivided into oncology, cardiovascular disease, neurology, immunology, and other therapeutic fields. Due to the rising incidence of cancer and the growing number of clinical trials and research focusing on cancer treatment and prevention, the oncology segment leads the market.

Pharmaceutical And Medical Device Firms Are Anticipated to be The Fastest Growing End Users Segment

The rapid rise of pharmaceutical and medical device firms is attributable to the growing significance of RWE studies in medication approvals, the prevention of costly drug recalls, and the evaluation of therapeutic performance in real-world contexts. In addition, the pharmaceutical industry's use of RWE continues to rise due to its application in addressing regulatory compliance requirements and payer obligations connected to HEOR. Pharmaceutical businesses demand information detailing both the approved and medically acknowledged alternative uses for previously approved medications. For novel medications to effectively progress through clinical phases, RWE data is required. Therefore, the successful phase transition is contingent upon robust real-world results.

North America remains the Global Leader, and APAC is the Growth Leader

North America held the greatest share of the RWE solutions market, while Asia-Pacific is anticipated to maintain the highest growth rate over the forecast period. Supporting the growth of the RWE solutions market in the Asia Pacific region are factors such as the rising number of clinical trials, increasing government initiatives for the adoption of RWE studies, the rising incidence of chronic diseases, the rising demand for better healthcare services, and the rising geriatric population. Moreover, nations such as Japan and China in the region have a well-established clinical trial infrastructure, a strong medical workforce, solid healthcare capabilities, and high-quality requirements, all of which contribute to the growth of the market in the Asia Pacific.

Market Competition to Intensify During the Forecast Period

The worldwide market is highly fragmented and competitive. Through subsidiaries and partnerships, market participants implement strategic initiatives such as product development and launch, distribution network expansion, and global footprint expansion. In addition to portfolio diversification and mergers & acquisitions, key players engage in portfolio diversification and mergers & acquisitions. For example, in August 2021, Syneos Health teamed with Aetion to develop a solution based on real-world evidence and to give analytically-driven data and regulatory-grade data. Similarly, Thermo Fisher Scientific announced in April 2021 that it will purchase PPD, Inc. for USD 47.50 per share. The key companies that are active in the market include IQVIA, IBM, ICON plc., PAREXEL International Corporation, PPD, LLC, Optum, Inc., Cognizant Technology Solutions Corporation, Oracle Corporation, SAS Institute Inc., Syneos Health, Inc., Anthem, Inc., Clinigen Group plc., Medpace Holdings Inc., Flatiron Health and Other notable players.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Real World Evidence Solution market are as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Real World Evidence Solution market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Component

  • Services
  • Data Sets
  • Disparate Data Sets
  • Clinical Settings Data
  • Claims Data
  • Pharmacy Data
  • Patient-Powered Data
  • Registry-Based Data Sets
  • Integrated Data Sets

Application

  • Drug Development And Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Disease
  • Other Therapeutic Areas
  • Medical Device Development And Approvals
  • Post-Market Surveillance
  • Market Access Reimbursement/Coverage Decision Making
  • Clinical And Regulatory Decision-Making

End User

  • Pharmaceutical & Medical Device Companies
  • Healthcare Providers
  • Healthcare Payers
  • Other End Users

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Real World Evidence Solution market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Real World Evidence Solution market?
  • Which is the largest regional market for Real World Evidence Solution market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Real World Evidence Solution market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Real World Evidence Solution market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Real World Evidence Solution Market
2.2. Global Real World Evidence Solution Market, By Component, 2022 (US$ Million)
2.3. Global Real World Evidence Solution Market, By Application, 2022 (US$ Million)
2.4. Global Real World Evidence Solution Market, By End User, 2022 (US$ Million)
2.5. Global Real World Evidence Solution Market, By Geography, 2022 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2022

3. Real World Evidence Solution Market: Competitive Analysis
3.1. Market Positioning of Key Real World Evidence Solution Market Vendors
3.2. Strategies Adopted by Real World Evidence Solution Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031

4. Real World Evidence Solution Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Real World Evidence Solution Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
5.3.1. Services
5.3.2. Data Sets
5.3.2.1. Disparate Data Sets
5.3.2.1.1. Clinical Settings Data
5.3.2.1.2. Claims Data
5.3.2.1.3. Pharmacy Data
5.3.2.1.4. Patient-Powered Data
5.3.2.1.5. Registry-Based Data Sets
5.3.2.2. Integrated Data Sets

6. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
6.3.1. Drug Development And Approvals
6.3.1.1. Oncology
6.3.1.2. Neurology
6.3.1.3. Immunology
6.3.1.4. Cardiovascular Disease
6.3.1.5. Other Therapeutic Areas
6.3.1.6. Medical Device Development And Approvals
6.3.2. Post-Market Surveillance
6.3.3. Market Access Reimbursement/Coverage Decision Making
6.3.4. Clinical And Regulatory Decision-Making

7. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
7.3.1. Pharmaceutical & Medical Device Companies
7.3.2. Healthcare Providers
7.3.3. Healthcare Payers
7.3.4. Other End Users

8. North America Real World Evidence Solution Market, 2021-2031, USD (Million)
8.1. Market Overview
8.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
8.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
8.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
8.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
8.5.1.North America
8.5.1.1. U.S.
8.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
8.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
8.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
8.5.1.2. Canada
8.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
8.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
8.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
8.5.1.3. Rest of North America
8.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
8.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
8.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)

9. UK and European Union Real World Evidence Solution Market, 2021-2031, USD (Million)
9.1. Market Overview
9.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
9.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
9.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
9.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
9.5.1.UK and European Union
9.5.1.1. UK
9.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
9.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
9.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
9.5.1.2. Germany
9.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
9.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
9.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
9.5.1.3. Spain
9.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
9.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
9.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
9.5.1.4. Italy
9.5.1.4.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
9.5.1.4.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
9.5.1.4.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
9.5.1.5. France
9.5.1.5.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
9.5.1.5.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
9.5.1.5.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
9.5.1.6. Rest of Europe
9.5.1.6.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
9.5.1.6.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
9.5.1.6.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)

10. Asia Pacific Real World Evidence Solution Market, 2021-2031, USD (Million)
10.1. Market Overview
10.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
10.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
10.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
10.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
10.5.1.Asia Pacific
10.5.1.1. China
10.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
10.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
10.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
10.5.1.2. Japan
10.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
10.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
10.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
10.5.1.3. India
10.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
10.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
10.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
10.5.1.4. Australia
10.5.1.4.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
10.5.1.4.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
10.5.1.4.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
10.5.1.5. South Korea
10.5.1.5.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
10.5.1.5.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
10.5.1.5.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
10.5.1.6. Rest of Asia Pacific
10.5.1.6.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
10.5.1.6.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
10.5.1.6.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)

11. Latin America Real World Evidence Solution Market, 2021-2031, USD (Million)
11.1. Market Overview
11.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
11.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
11.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
11.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
11.5.1.Latin America
11.5.1.1. Brazil
11.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
11.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
11.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
11.5.1.2. Mexico
11.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
11.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
11.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
11.5.1.3. Rest of Latin America
11.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
11.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
11.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)

12. Middle East and Africa Real World Evidence Solution Market, 2021-2031, USD (Million)
12.1. Market Overview
12.2. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
12.3. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
12.4. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
12.5.Real World Evidence Solution Market: By Region, 2021-2031, USD (Million)
12.5.1.Middle East and Africa
12.5.1.1. GCC
12.5.1.1.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
12.5.1.1.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
12.5.1.1.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
12.5.1.2. Africa
12.5.1.2.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
12.5.1.2.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
12.5.1.2.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)
12.5.1.3. Rest of Middle East and Africa
12.5.1.3.1. Real World Evidence Solution Market: By Component, 2021-2031, USD (Million)
12.5.1.3.1. Real World Evidence Solution Market: By Application, 2021-2031, USD (Million)
12.5.1.3.1. Real World Evidence Solution Market: By End User, 2021-2031, USD (Million)

13. Company Profile
13.1. IQVIA (US)
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. IBM (US)
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. ICON plc. (Ireland)
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. PAREXEL International Corporation (US)
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. PPD, LLC (US)
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Optum, Inc. (US)
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. Cognizant Technology Solutions Corporation (US)
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Oracle Corporation (US)
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
13.9. SAS Institute Inc. (US)
13.9.1. Company Overview
13.9.2. Financial Performance
13.9.3. Product Portfolio
13.9.4. Strategic Initiatives
13.10. Syneos Health, Inc. (US)
13.10.1. Company Overview
13.10.2. Financial Performance
13.10.3. Product Portfolio
13.10.4. Strategic Initiatives
13.11. Anthem, Inc. (US)
13.11.1. Company Overview
13.11.2. Financial Performance
13.11.3. Product Portfolio
13.11.4. Strategic Initiatives
13.12. Clinigen Group plc. (UK)
13.12.1. Company Overview
13.12.2. Financial Performance
13.12.3. Product Portfolio
13.12.4. Strategic Initiatives
13.13. Medpace Holdings Inc. (US)
13.13.1. Company Overview
13.13.2. Financial Performance
13.13.3. Product Portfolio
13.13.4. Strategic Initiatives
13.14. Flatiron Health (US)
13.14.1. Company Overview
13.14.2. Financial Performance
13.14.3. Product Portfolio
13.14.4. Strategic Initiatives
13.15. Others
13.15.1. Company Overview
13.15.2. Financial Performance
13.15.3. Product Portfolio
13.15.4. Strategic Initiatives

List of Figures
Figure 1 Global Real World Evidence Solution Market: Market Coverage FIG. 2 Research Methodology and Data Sources FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach FIG. 4 Global Real World Evidence Solution Market: Quality Assurance FIG. 5 Global Real World Evidence Solution Market, By Component, 2022 FIG. 6 Global Real World Evidence Solution Market, By Application, 2022 FIG. 7 Global Real World Evidence Solution Market, By End User, 2022 FIG. 8 Global Real World Evidence Solution Market, By Geography, 2022 FIG. 9 Market Geographical Opportunity Matrix - Global Real World Evidence Solution Market, 2022 FIG. 10 Market Positioning of Key Real World Evidence Solution Market Players, 2022 FIG. 11 Global Real World Evidence Solution Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031 FIG. 12 Global Real World Evidence Solution Market, By Component, 2022 Vs 2031, % FIG. 13 Global Real World Evidence Solution Market, By Application, 2022 Vs 2031, % FIG. 14 Global Real World Evidence Solution Market, By End User, 2022 Vs 2031, % FIG. 15 U.S. Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 16 Canada Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 17 Rest of North America Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 18 UK Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 19 Germany Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 20 Spain Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 21 Italy Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 22 France Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 23 Rest of Europe Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 24 China Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 25 Japan Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 26 India Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 27 Australia Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 28 South Korea Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 29 Rest of Asia Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 30 Brazil Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 31 Mexico Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 32 Rest of Latin America Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 33 GCC Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 34 Africa Real World Evidence Solution Market (US$ Million), 2021 - 2031 FIG. 35 Rest of Middle East and Africa Real World Evidence Solution Market (US$ Million), 2021 - 2031

List of Tables
Table 1 Global Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 12 Global Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 13 Global Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 14 Global Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 15 Global Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 16 Global Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 17 North America Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 18 North America Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 19 North America Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 110 North America Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 111 North America Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 112 North America Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 113 U.S. Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 114 U.S. Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 115 U.S. Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 116 U.S. Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 117 U.S. Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 118 U.S. Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 119 Canada Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 120 Canada Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 121 Canada Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 122 Canada Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 123 Canada Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 124 Canada Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 125 Rest of North America Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 126 Rest of North America Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 127 Rest of North America Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 128 Rest of North America Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 129 Rest of North America Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 130 Rest of North America Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 131 UK and European Union Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 132 UK and European Union Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 133 UK and European Union Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 134 UK and European Union Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 135 UK and European Union Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 136 UK and European Union Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 137 UK Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 138 UK Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 139 UK Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 140 UK Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 141 UK Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 142 UK Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 143 Germany Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 144 Germany Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 145 Germany Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 146 Germany Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 147 Germany Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 148 Germany Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 149 Spain Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 150 Spain Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 151 Spain Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 152 Spain Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 153 Spain Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 154 Spain Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 155 Italy Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 156 Italy Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 157 Italy Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 158 Italy Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 159 Italy Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 160 Italy Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 161 France Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 162 France Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 163 France Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 164 France Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 165 France Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 166 France Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 167 Rest of Europe Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 168 Rest of Europe Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 169 Rest of Europe Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 170 Rest of Europe Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 171 Rest of Europe Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 172 Rest of Europe Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 173 Asia Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 174 Asia Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 175 Asia Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 176 Asia Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 177 Asia Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 178 Asia Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 179 China Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 180 China Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 181 China Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 182 China Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 183 China Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 184 China Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 185 Japan Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 186 Japan Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 187 Japan Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 188 Japan Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 189 Japan Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 190 Japan Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 191 India Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 192 India Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 193 India Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 194 India Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 195 India Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 196 India Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 197 Australia Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 198 Australia Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 199 Australia Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1100 Australia Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1101 Australia Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1102 Australia Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1103 South Korea Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1104 South Korea Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1105 South Korea Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1106 South Korea Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1107 South Korea Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1108 South Korea Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1109 Latin America Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1110 Latin America Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1111 Latin America Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1112 Latin America Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1113 Latin America Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1114 Latin America Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1115 Brazil Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1116 Brazil Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1117 Brazil Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1118 Brazil Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1119 Brazil Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1120 Brazil Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1121 Mexico Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1122 Mexico Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1123 Mexico Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1124 Mexico Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1125 Mexico Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1126 Mexico Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1127 Rest of Latin America Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1128 Rest of Latin America Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1129 Rest of Latin America Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1130 Rest of Latin America Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1131 Rest of Latin America Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1132 Rest of Latin America Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1133 Middle East and Africa Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1134 Middle East and Africa Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1135 Middle East and Africa Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1136 Middle East and Africa Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1137 Middle East and Africa Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1138 Middle East and Africa Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1139 GCC Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1140 GCC Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1141 GCC Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1142 GCC Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1143 GCC Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1144 GCC Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1145 Africa Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1146 Africa Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1147 Africa Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1148 Africa Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1149 Africa Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1150 Africa Real World Evidence Solution Market By End User, 2021-2031, USD (Million)
Table 1151 Rest of Middle East and Africa Real World Evidence Solution Market By Component, 2021-2031, USD (Million)
Table 1152 Rest of Middle East and Africa Real World Evidence Solution Market By Data Sets, 2021-2031, USD (Million)
Table 1153 Rest of Middle East and Africa Real World Evidence Solution Market By Disparate Data Sets, 2021-2031, USD (Million)
Table 1154 Rest of Middle East and Africa Real World Evidence Solution Market By Application, 2021-2031, USD (Million)
Table 1155 Rest of Middle East and Africa Real World Evidence Solution Market By Drug Development And Approvals, 2021-2031, USD (Million)
Table 1156 Rest of Middle East and Africa Real World Evidence Solution Market By End User, 2021-2031, USD (Million)

Companies Mentioned

  • IQVIA
  • IBM
  • ICON plc.
  • PAREXEL International Corporation
  • PPD LLC
  • Optum Inc
  • Cognizant Technology Solutions Corporation
  • Oracle Corporation
  • SAS Institute Inc.
  • Syneos Health Inc
  • Anthem Inc
  • Clinigen Group plc.
  • Medpace

Related Topics

Related Reports

Global Real World Evidence Solutions Market by Component (Services, Disparate Data Sets (Clinical), Application (Drug and Medical Device Development and Approvals), Mode of Deployment, Revenue Model, End-users, & Region, Business Model - Forecast to 2029 - Product Image

Global Real World Evidence Solutions Market by Component (Services, Disparate Data Sets (Clinical), Application (Drug and Medical Device Development and Approvals), Mode of Deployment, Revenue Model, End-users, & Region, Business Model - Forecast to 2029

  • Report
  • 412 Pages
  • Global
From
Global Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, Data Sets), Application, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Global Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, Data Sets), Application, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 200 Pages
  • Global
From
Global Real-World Evidence Solutions - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Global Real-World Evidence Solutions - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 118 Pages
  • Global
From
Real World Evidence Solutions Global Market Report 2024 - Product Image

Real World Evidence Solutions Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Real World Evidence Solution Market by Component (Data Set, Services), Therapeutic Area (Cardiovascular, Immunology, Infectious Diseases), End-User - Forecast 2023-2030 - Product Image

Global Real World Evidence Solution Market by Component (Data Set, Services), Therapeutic Area (Cardiovascular, Immunology, Infectious Diseases), End-User - Forecast 2023-2030

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.